Merck KGAA/Pfizer's Bavencio Failure Casts More Shade On Immunotherapy For Ovarian Cancer
Phase III first-line JAVELIN Ovarian 100 study fails, but trial combining Bavencio with PARP inhbitor Talzenna in similar setting goes on.
Phase III first-line JAVELIN Ovarian 100 study fails, but trial combining Bavencio with PARP inhbitor Talzenna in similar setting goes on.